Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results...
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
About this item
Full title
Author / Creator
Leonardi, Craig , Reich, Kristian , Foley, Peter , Torii, Hideshi , Gerdes, Sascha , Guenther, Lyn , Gooderham, Melinda , Ferris, Laura K. , Griffiths, Christopher E. M. , ElMaraghy, Hany , Crane, Heidi , Patel, Himanshu , Burge, Russel , Gallo, Gaia , Shrom, David , Leung, Ann , Lin, Chen-Yen and Papp, Kim
Publisher
Cheshire: Springer Healthcare
Journal title
Language
English
Formats
Publication information
Publisher
Cheshire: Springer Healthcare
Subjects
More information
Scope and Contents
Contents
Introduction
Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for treatment of moderate-to-severe plaque psoriasis. Our objective was to evaluate the long-term efficacy and safety of ixekizumab in moderate-to-severe plaque psoriasis through 5 years.
Methods
Data were integrated from the...
Alternative Titles
Full title
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9fcdd75b0c314187bca955c0a6fd2339
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9fcdd75b0c314187bca955c0a6fd2339
Other Identifiers
ISSN
2193-8210
E-ISSN
2190-9172
DOI
10.1007/s13555-020-00367-x
